

### Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application.

#### Listing of Claims

1. (Currently Amended) A purified mature BNP2 polypeptide comprising an amino acid sequence ~~selected from the group consisting of:~~
  - a) ~~the amino acid sequence of SEQ ID NO:1, 3, or 36;~~
  - b) ~~a sequence having at least seven contiguous residues of the amino acid sequence of SEQ ID NO:1;~~
  - e) ~~a sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO:1; and~~
  - d) ~~a sequence having at least 85% sequence identity to a fragment of SEQ ID NO:1 at least seven contiguous residues in length.~~
- 2-5. (Cancelled)
6. (Currently Amended) The polypeptide of claim 1, wherein said polypeptide comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 1.
7. (Cancelled)
8. (Currently Amended) The polypeptide of claim 1, wherein said polypeptide comprises an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1.
9. (Cancelled)
10. (Previously Presented) The polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:36.
11. (Withdrawn) An isolated nucleic acid encoding said polypeptide of claim 1.

12. (Withdrawn) The isolated nucleic acid of claim 11, wherein said polypeptide is encoded by

- i) the nucleic acid sequence of SEQ ID NO:5;
- ii) the nucleic acid sequence of nucleotides 383 to 489 of SEQ ID NO:5;
- iii) the nucleic acid sequence of SEQ ID NO:6; or
- iv) the nucleic acid sequence of nucleotides 388 to 432 of SEQ ID NO:6.

13. (Withdrawn) A vector comprising the nucleic acid of claim 12.

14. (Withdrawn) Host cells comprising the vector of claim 13.

15. (Withdrawn) The host cells of claim 14, wherein said host cells are eukaryotic host cells.

16. (Currently Amended) A pharmaceutical composition comprising the a mature BNP2 polypeptide of claim 1 comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO:1, and a pharmaceutically acceptable carrier.

17. (Withdrawn) An antibody having specific binding affinity for the polypeptide of claim 1.

18. (Withdrawn) A chimeric natriuretic polypeptide comprising a first region and a second region, said first region having an amino acid sequence selected from the group consisting of:

- a) the sequence of residues 1 to 27 of SEQ ID NO:16;
- b) the sequence of residues 1 to 25 of SEQ ID NO:17;
- c) the sequence of residues 1 to 23 of SEQ ID NO:18;
- d) the sequence of residues 1 to 22 of SEQ ID NO:19; and
- e) the sequence of a), b), c), or d) with one to five amino acid substitutions;

said second region having an amino acid sequence selected from the group consisting of:

- f) the sequence of SEQ ID NO:1 or SEQ ID NO:2;
- g) a sequence having at least 6 contiguous residues of the amino acid sequence of SEQ

ID NO:1 or SEQ ID NO:2;

h) a sequence having at least 65% sequence identity to the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2; and

i) a sequence having at least 65% sequence identity to a fragment of SEQ ID NO:1 or SEQ ID NO:2 at least six contiguous residues in length.

19. (Withdrawn) A purified polypeptide comprising an amino acid sequence of the formula:  
Gly-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Xaa<sub>4</sub>-Xaa<sub>5</sub>-Xaa<sub>6</sub>-Xaa<sub>7</sub>-Xaa<sub>8</sub>-Xaa<sub>9</sub>-Xaa<sub>10</sub>-Xaa<sub>11</sub>-Xaa<sub>12</sub>-Xaa<sub>13</sub>-Xaa<sub>14</sub>-  
Xaa<sub>15</sub>-Xaa<sub>16</sub>-Xaa<sub>17</sub>-Xaa<sub>18</sub>-Xaa<sub>19</sub>-Xaa<sub>20</sub>-Xaa<sub>21</sub>-Xaa<sub>22</sub>-Xaa<sub>23</sub>-Xaa<sub>24</sub>-Xaa<sub>25</sub>-Xaa<sub>26</sub>-Xaa<sub>27</sub>-  
Xaa<sub>28</sub>-Gly-Xaa<sub>29</sub>-Xaa<sub>30</sub>-Xaa<sub>31</sub>-Xaa<sub>32</sub> (SEQ ID NO:20),

wherein Xaa<sub>1</sub> is Glu or Lys; Xaa<sub>2</sub> is Pro, His, or Arg; Xaa<sub>3</sub> is Pro or Leu; Xaa<sub>4</sub> is Pro, Leu, or Ser; Xaa<sub>5</sub> is Cys or Pro; Xaa<sub>6</sub> is Pro, His, Gln, or Arg; Xaa<sub>7</sub> is Arg, Phe, or Leu; Xaa<sub>8</sub> is Asp, Gly, or absent; Xaa<sub>9</sub> is Ser, Pro, or Leu; Xaa<sub>10</sub> is Pro or absent; Xaa<sub>11</sub> is Ser, Ala, or absent; Xaa<sub>12</sub> is Pro or Ala; Xaa<sub>13</sub> is Ala, Phe, Ile, or Leu; Xaa<sub>14</sub> is Pro, Lys, or Leu; Xaa<sub>15</sub> is Val, Leu, or Trp; Xaa<sub>16</sub> is Cys, His, or Val; Xaa<sub>17</sub> is Asp, Ala, Ile, Thr, Pro, or Arg; Xaa<sub>18</sub> is Thr, Pro, or His; Xaa<sub>19</sub> is Val, Ile, Pro, Val, Ser, or Leu; Xaa<sub>20</sub> is Arg, Ser, Ile, or Glu; Xaa<sub>21</sub> is Val, Ile, Ala, or Pro; Xaa<sub>22</sub> is Thr, Val, or Leu; Xaa<sub>23</sub> is Leu, Ser, or His; Xaa<sub>24</sub> is Gly or Ala; Xaa<sub>25</sub> is Phe, Ser, Thr, or Leu; Xaa<sub>26</sub> is Val, Asp, or Leu; Xaa<sub>27</sub> is Val, Leu, or Ser; Xaa<sub>28</sub> is Ser, Arg, or Leu; Xaa<sub>29</sub> is Asn, Asp, Pro, or Thr; Xaa<sub>30</sub> is His, Gln, Asn, or Thr; Xaa<sub>31</sub> is Thr, Ile, or Ser; and Xaa<sub>32</sub> is Pro, Leu, or Glu.

20. (Withdrawn) A method for diagnosing a heart condition in a patient, said method comprising:

- a) providing a biological sample from said patient;
  - b) detecting the presence, absence, or level of BNP2 or BNP3 in said biological sample;
- and
- c) classifying said patient as having said heart condition or not having said heart condition based, at least in part, on the presence of BNP-2 or BNP-3, the level of BNP2 or BNP3, or the absence of BNP2 or BNP3.

21. (Withdrawn) The method of claim 20, wherein said heart condition is heart failure.

22. (Withdrawn) The method of claim 20, wherein said heart condition is unstable angina.

23. (Withdrawn) The method of claim 20, wherein said heart condition is acute myocardial infarction.

24. (Withdrawn) The method of claim 20, wherein said heart condition is hypertension.

25. (Withdrawn) The method of claim 20, wherein the presence, absence, or level of BNP2 is detected.

26. (Withdrawn) The method of claim 20, wherein the presence, absence, or level of BNP3 is detected.

27. (Withdrawn) A method for diagnosing a heart condition in a patient, said method comprising:

- a) providing a biological sample from said patient;
- b) detecting the presence, absence, or level of a ribonucleic acid encoding BNP2 or BNP3 in said biological sample; and
- c) classifying said patient as having said heart condition or not having said heart condition based, at least in part, on the presence of said ribonucleic acid encoding BNP2 or BNP3, the level of said ribonucleic acid encoding BNP2 or BNP3, or the absence of said ribonucleic acid encoding BNP2 or BNP3.

28. (Withdrawn) The method of claim 27, wherein said heart condition is heart failure.

29. (Withdrawn) The method of claim 27, wherein said heart condition is unstable angina.

30. (Withdrawn) The method of claim 27, wherein said heart condition is acute myocardial infarction.

31. (Withdrawn) The method of claim 27, wherein said heart condition is hypertension.

32. (Withdrawn-Previously Presented) A method for treating a heart condition in a mammal, said method comprising administering a polypeptide or a nucleic acid to said mammal under conditions wherein the severity of a symptom of said heart condition is reduced, wherein said

polypeptide is a polypeptide of claim 1, and wherein said nucleic acid is a nucleic acid of claim 11.

33. (Withdrawn) The method of claim 32, wherein said method comprises administering said polypeptide.

34. (Withdrawn) The method of claim 32, wherein said method comprises administering said nucleic acid.

35. (Withdrawn) The method of claim 32, wherein said heart condition is heart failure.

36. (Withdrawn) The method of claim 32, wherein said heart condition is unstable angina.

37. (Withdrawn) The method of claim 32, wherein said heart condition is acute myocardial infarction.

38. (Withdrawn) The method of claim 32, wherein said heart condition is hypertension.

39. (Withdrawn) A purified antibody, wherein said antibody binds to a BNP2 polypeptide, and wherein said antibody does not bind to a BNP polypeptide consisting of the sequence set forth in SEQ ID NO:16 or to a BNP3 polypeptide consisting of the sequence set forth in SEQ ID NO:4.

40. (Withdrawn) The antibody of claim 39, wherein said BNP2 polypeptide comprises the sequence set forth in SEQ ID NO:1.

41. (Withdrawn) The antibody of claim 39, wherein said antibody is a monoclonal antibody.

42. (Withdrawn) A purified antibody, wherein said antibody binds to a BNP3 polypeptide, and wherein said antibody does not bind to a BNP polypeptide consisting of the sequence set forth in SEQ ID NO:16 or to a BNP2 polypeptide consisting of the sequence set forth in SEQ ID NO:3.

43. (Withdrawn) The antibody of claim 42, wherein said BNP3 polypeptide comprises the sequence set forth in SEQ ID NO:2.
44. (Withdrawn) The antibody of claim 42, wherein said antibody is a monoclonal antibody.